FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer

SIMPLE SUMMARY: In breast cancer, the promising efficacy of farnesyltransferase inhibitors (FTIs) in preclinical studies is in contrast to only limited effects in clinical trials. Therefore, this study focussed on the clinical relevance of polymorphisms in FNTB, the gene encoding the catalytically a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachmann, Hagen Sjard, Jung, Dominik, Link, Theresa, Arnold, Anna, Kantelhardt, Eva, Thomssen, Christoph, Wimberger, Pauline, Vetter, Martina, Kuhlmann, Jan Dominik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833514/
https://www.ncbi.nlm.nih.gov/pubmed/35158735
http://dx.doi.org/10.3390/cancers14030468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833514/
https://www.ncbi.nlm.nih.gov/pubmed/35158735
http://dx.doi.org/10.3390/cancers14030468

Ejemplares similares